escitalopram / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   144 Trials   144 Trials   2302 News 


«12...1011121314151617181920...5152»
  • ||||||||||  escitalopram / Generic mfg.
    Preclinical, Journal:  Formulation Development and in-vitro Evaluation of Escitalopram Fast Dissolving Tablets. (Pubmed Central) -  Jun 25, 2022   
    The literature cannot at this stage determine evidence-based pharmacological treatments for PUI. As a result, after confirming in-vivo potential, the created fast release formulation exhibited impressive in-vitro findings and may prove to be a boon in treating acute depression attacks.
  • ||||||||||  Review, Journal:  Menopause and Sleep Disorders. (Pubmed Central) -  Jun 22, 2022   
    Hormone replacement therapy presently lacks concrete evidence to be used in menopausal women for sleep disorder. Sleep hygiene practices, self-hypnosis, meditation, and exercise play a very important role.
  • ||||||||||  nortriptyline / Generic mfg., escitalopram / Generic mfg.
    Clinical, Journal:  A Randomized Clinical Trial Comparing Two Treatment Strategies, Evaluating the Meaningfulness of HAM-D Rating Scale in Patients With Major Depressive Disorder. (Pubmed Central) -  Jun 22, 2022   
    Evaluation of both the absolute HAM-D scores and four factors derived from the HAM-D (depressed mood, sleep, psychic and somatic anxiety and suicidal ideation) revealed that the latter showed a greater promise in gauging the anti-depressant responses. The study confirms the assumption that while both drugs may improve several items on the HAM-D scale, the overall protocol may fall short of addressing the symptoms diversity in MDD and thus the analysis of factor (s) in question might be more relevant and meaningful.
  • ||||||||||  Clinical, Journal:  Risk of out-of-hospital cardiac arrest in antidepressant drug users. (Pubmed Central) -  Jun 19, 2022   
    The study confirms the assumption that while both drugs may improve several items on the HAM-D scale, the overall protocol may fall short of addressing the symptoms diversity in MDD and thus the analysis of factor (s) in question might be more relevant and meaningful. Our findings indicate that careful titration of citalopram, escitalopram and mirtazapine dose may have to be considered due to drug safety issues.
  • ||||||||||  escitalopram / Generic mfg.
    Phase classification, Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  LABCATTCJUSS: Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode (clinicaltrials.gov) -  Jun 16, 2022   
    P3,  N=111, Terminated, 
    Our findings indicate that careful titration of citalopram, escitalopram and mirtazapine dose may have to be considered due to drug safety issues. Phase classification: P2/3 --> P3 | N=282 --> 111 | Trial completion date: Aug 2020 --> Jun 2022 | Unknown status --> Terminated | Trial primary completion date: Aug 2020 --> Jun 2022; Recruitment difficulties due to monocentric study
  • ||||||||||  citalopram / Generic mfg., escitalopram / Generic mfg.
    Journal:  Concentrations of citalopram and escitalopram in postmortem hair segments. (Pubmed Central) -  Jun 15, 2022   
    The median R/S-ratio of citalopram in hair was 1.5 and was similar to previously reported ratios in blood. In the present study, we report concentrations of citalopram and escitalopram in postmortem hair and their relation to an estimated daily dose and thus contribute valuable information in forensic investigations.
  • ||||||||||  dextroamphetamine immediate release / Generic mfg., escitalopram / Generic mfg.
    Journal:  Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. (Pubmed Central) -  Jun 9, 2022   
    Reoccurring drug-like experiences after the administration of LSD and psilocybin are a common phenomenon occurring in up to 9.2% of healthy subjects (7.8% for LSD, 8.3% for psilocybin and 14.3% if both substances are administered). Additionally, our work suggests that flashback phenomena are not a clinically relevant problem in controlled studies with healthy participants.
  • ||||||||||  escitalopram / Generic mfg.
    Journal:  Effects of escitalopram therapy on functional brain controllability in major depressive disorder. (Pubmed Central) -  Jun 9, 2022   
    Our results also showed that the changes of global average and modal controllability measures can predict the improvements of clinical scores of the MDD patients as the escitalopram treatment advanced (P < 0.05). In conclusion, this study reveals promising brain controllability-based biomarkers to mechanistically understand and predict the effects of the escitalopram treatment for depression and maybe extended to predict and understand the effects of other interventions for other neurological and psychiatric diseases.
  • ||||||||||  levetiracetam / Generic mfg., escitalopram / Generic mfg.
    Preclinical, Journal:  Spontaneous alternation and stereotypical behaviour in deer mice: response to escitalopram and levetiracetam. (Pubmed Central) -  Jun 4, 2022   
    While levetiracetam increased the time spent engaging in normal rodent activity by Comp-H, but not Norm-N animals, neither of the interventions affected the expression of Comp-H behaviour or the alternation behaviour of deer mice. In conclusion, this work points to some degree of cognitive involvement in Comp-H expression, which should be explored to further our understanding of compulsive-like stereotypy.
  • ||||||||||  escitalopram / Generic mfg.
    Trial completion, Enrollment change:  Advancing Personalized Antidepressant Treatment Using PET/MRI (clinicaltrials.gov) -  Jun 2, 2022   
    P4,  N=85, Completed, 
    To address this issue, regulatory organizations should establish and verify validation and reporting mechanisms. Recruiting --> Completed | N=150 --> 85
  • ||||||||||  Review, Journal:  Repurposing Autophagy Regulators in Brain Tumors. (Pubmed Central) -  May 29, 2022   
    Sertraline and desipramine, depending on the neoplastic context, were demonstrated to either induce or inhibit autophagy. Collectively, these medications were associated with favorable therapeutic outcomes in a variety of cancer cell models, including brain tumors.
  • ||||||||||  escitalopram / Generic mfg.
    Journal:  Anxiolytic and antidepressants' effect of Crataegus pinnatifida (Shan Zha): biochemical mechanisms. (Pubmed Central) -  May 29, 2022   
    In the current study, we examined the antidepressant-like and anxiolytic-like activities of each individual herb on stressed mice and compared those to the effects of NHT and escitalopram...Notably, Shan Zha is sold as a nutritional supplement; thus, its transition to clinical trials can be easier. Once its efficacy and safety are substantiated, Shan Zha may serve as an alternative to conventional antidepressants.
  • ||||||||||  vildagliptin / Generic mfg.
    Trial completion date, Trial primary completion date:  The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients (clinicaltrials.gov) -  May 26, 2022   
    P1/2,  N=100, Recruiting, 
    [ClinicalTrials.gov], identifier [NCT03909217]. Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: May 2022 --> Dec 2022
  • ||||||||||  duloxetine / Generic mfg., escitalopram / Generic mfg.
    Biomarker, Journal:  Systemic DNA and RNA damage from oxidation after serotonergic treatment of unipolar depression. (Pubmed Central) -  May 25, 2022   
    We conclude that intervention with serotonin reuptake inhibitors in unipolar depression is associated with a reduction in systemic DNA and RNA damage from oxidation. To our knowledge, this to date the largest intervention study to characterize this phenomenon, and the first to include a marker of RNA oxidation.
  • ||||||||||  Journal:  Antidepressants induce toxicity in human placental BeWo cells. (Pubmed Central) -  May 24, 2022   
    Sertraline may induce ROS-dependent apoptosis in human placental cells. These results are useful for further studies to determine the optimal dosage of antidepressants for pregnant women.
  • ||||||||||  amitriptyline / Generic mfg., sertraline / Generic mfg., escitalopram / Generic mfg.
    Journal, Adverse events:  Understanding genetic risk factors for common side effects of antidepressant medications. (Pubmed Central) -  May 24, 2022   
    Insomnia PRS show some evidence of predicting insomnia from amitriptyline and escitalopram...These factors seem to be partly explained by genetic liability related to depression severity and the nature of the side effect. Future studies on the genetic aetiology of side effects will enable insights into their underlying mechanisms and the possibility of risk stratification and prophylaxis strategies.
  • ||||||||||  escitalopram / Generic mfg.
    Journal:  Binding potential changes of SERT in patients with depression are associated with remission: A prospective [¹²³I]β-CIT-SPECT study. (Pubmed Central) -  May 24, 2022   
    [¹²³I]2β-carbomethoxy-3β-(4-iodophenyl)tropane(β-CIT) SPECT was obtained from each participant before (baseline) and after 6 weeks (follow-up) of standardized treatment with escitalopram...Therefore, this study shows that measuring SERT availability with SPECT could be an efficient and applicable technique to illustrate a possible underlying pathophysiology of symptom remission in response to treatment. In addition, the present results could help to stimulate new treatment approaches based on SERT and DAT binding.
  • ||||||||||  duloxetine / Generic mfg., escitalopram / Generic mfg.
    Journal:  Emotional faces processing in major depressive disorder and prediction of antidepressant treatment response: A NeuroPharm study. (Pubmed Central) -  May 21, 2022   
    P1
    This represents the largest prediction study to date examining emotional faces fMRI features as predictors of antidepressant treatment response. Brain response to this fMRI emotional faces paradigm did not distinguish depressed individuals from healthy controls, nor was it predictive of antidepressant treatment response.Clinical Trial Registration: Site: https://clinicaltrials.gov, Trial Number: NCT02869035, Trial Title: Treatment Outcome in Major Depressive Disorder.
  • ||||||||||  methamphetamine / Generic mfg., escitalopram / Generic mfg.
    Journal:  Allosteric Binding of MDMA to the Human Serotonin Transporter (hSERT) via Ensemble Binding Space Analysis with ΔG Calculations, Induced Fit Docking and Monte Carlo Simulations. (Pubmed Central) -  May 21, 2022   
    Despite the recent promising results of MDMA (3,4-methylenedioxy-methamphetamine) as a psychotherapeutic agent and its history of misuse, little is known about its molecular mode of action...Simulations on all hSERT available structures with Gibbs free energy estimations (ΔG) revealed a favourable and pervasive dual binding mode for MDMA at S2, i.e., adopting either a 5-HT or an escitalopram-like orientation...Similitudes and differences with the allosteric binding of 5-HT and antidepressants suggest that MDMA may have a distinctive chemotype. Thus, our models may provide a framework for future virtual screening studies and pharmaceutical design and to develop hSERT allosteric compounds with a unique psychoactive MDMA-like profile.